RxDoctor Payments Data

Arka Chatterjee, MD

Interventional Cardiology · Birmingham, ALNPI 1578890992

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Edwards Lifesciences at 52.0% of the total.

$16,461in general payments, 2019–2025

Across 182 payments — averaging $90.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$9K
  • Abbott$3K
  • Angiodynamics, Inc.$1K
  • Medtronic$969
  • Abiomed$568
  • Shockwave Medical, Inc$436
  • plus $2K from 12 others
$11,578in research payments, 2019–2025

Across 5 payments — averaging $2315.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cardiovascular Systems Inc.$12K
  • Abiomed$50

What the payments were for

  • Consulting fees$2,50015%
  • Travel & lodging$4,71229%
  • Food & beverage$9,24956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,461 in reported general payments places this provider in the 75th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$144,382
Medicare patients
445
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$44,332
EntrestoSacubitril/Valsartan14$16,784
XareltoRivaroxaban12$15,308
Ranolazine ErRanolazine14$2,355
Metoprolol Succinate99$1,633
Rosuvastatin Calcium89$1,337
ClopidogrelClopidogrel Bisulfate81$1,202
Nitroglycerin PatchNitroglycerin20$896
Ezetimibe23$685
Telmisartan17$528
Losartan Potassium32$440
Atorvastatin Calcium67$431
Carvedilol61$375
Furosemide66$357
Nitroglycerin19$310

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →